Actively Recruiting
Phase 2 Study of Ifinatamab Deruxtecan I-DXd for Treating Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Therapy
Led by Merck Sharp & Dohme LLC · Updated on 2026-07-30
60
Participants Needed
23
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating if ifinatamab deruxtecan I-DXd, an antibody-drug conjugate, can treat advanced esophageal squamous cell carcinoma ESCC. This treatment works by attaching to proteins on cancer cells and delivering therapy to destroy them. The study aims to find out how many participants experience tumor shrinkage or disappearance after receiving I-DXd. Participants will receive I-DXd through intravenous infusion every 3 weeks. Treatment continues until the cancer progresses or other criteria for stopping are met. The study is part of a master screening protocol called KEYMAKER-U06 and focuses on participants with unresectable locally advanced or metastatic ESCC who have had prior systemic therapy. During the study, participants will be monitored for tumor response using objective response rate over about 14 months. Researchers will also measure duration of response, progression-free survival, overall survival, and track adverse events for up to 18 to 26 months. Participants undergo regular assessments including imaging and safety evaluations throughout their participation, which may last several months.
CONDITIONS
Brief Title
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
